Clinical Trial

PRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab)

Study acronym: PRONTO
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Despite the consequent use of Tocilizumab together with conventional antipyretics at early/first signs of emerging CRS, CRS (and eventually the subsequent development of ICANS) remain a major concern for patients. This study aims to identify safety and efficacy of prophylactic Tocilizumab treatment. In particular, to explore whether prophylactic Tocilizumab treatment can decrease the incidence and severity of CRS (and subsequent eventual neurotoxicity) following CAR-T-treatment.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-05-21.
Status change: Not Yet Recruiting → Recruiting 2024-07-04
Trial Details
NCT Number NCT06430736
Lead Sponsor Insel Gruppe AG, University Hospital Bern
Conditions Myeloma, Lymphoma, Leukemia
Enrollment 100 participants
Start Date 2024-07-01
Primary Completion 2026-12 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2024-07-08